Nature Search

Author Correction: E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis

Jay V. Patankar
Tanja M. Müller
Christoph Becker
Amendments and Corrections22 Dec 2025
Nature Cell Biology

P: 1
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

The use of antibodies against tumour necrosis factor (TNF) has markedly improved the treatment of Crohn's disease, but only certain patients respond to therapy. Here, Raja Atreya and colleagues have developed an approach using topical fluorescent antibodies to TNF and confocal laser endomicroscopy to evaluate the expression of transmembrane TNF (mTNF) in the intestinal mucosa of patients with active Crohn's disease in order to identify patients likely to respond to subsequent treatment with the anti-TNF therapy, adalimumab.

Raja Atreya
Helmut Neumann
Markus F Neurath
Research23 Feb 2014
Nature Medicine

Volume: 20, P: 313-318
Author Correction: Hobit- and Blimp-1-driven CD4⁺ tissue-resident memory T cells control chronic intestinal inflammation

Sebastian Zundler
Emily Becker
Markus F. Neurath
Amendments and Corrections07 Mar 2019
Nature Immunology

Volume: 20, P: 514
Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cells

The clinical success of anti- αEβ7 antibody Etrolizumab for Crohn’s disease is less than what is expected based on proof-of-concept studies. Here authors show, by characterization of T cells from Etrolizumab-treated patients, in vitro functional assays and reanalysis of public single cell datasets on Etrolizumab-treated patients, that at high level of T cell activation, which characterises T cells in Crohn’s disease, E-Cadherin-αEβ7 interactions become resistant to Etrolizumab inhibition.

Maximilian Wiendl
Mark Dedden
Sebastian Zundler
ResearchOpen Access03 Feb 2024
Nature Communications

Volume: 15, P: 1-14
Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019

Chronic care manages long-term, progressive conditions, while acute care handles short-term ones. Here, authors show chronic conditions account for most of the global health burden, with 68% of DALYs and 93% of YLDs attributed to chronic care needs.

Cecilia Anza-Ramirez
J. Jaime Miranda
Yves Miel H. Zuniga
ResearchOpen Access07 May 2025
Nature Communications

Volume: 16, P: 1-36
Correction: Corrigendum: T_H9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells

Katharina Gerlach
YouYi Hwang
Markus F Neurath
Amendments and Corrections16 Jan 2015
Nature Immunology

Volume: 16, P: 214
Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study

Systematic analysis from the Global Burden of Disease study reported that, despite global improvements from 1990 to 2021, dietary iron deficiency-associated disease burden remains high in women, children and residents in low socio-demographic index countries.

Sooji Lee
Yejun Son
Nicholas. J. Kassebaum
Research22 Apr 2025
Nature Medicine

Volume: 31, P: 1809-1829
Chromoendoscopy in IBD: indispensable in real-life screening

Long-standing IBD is associated with an increased risk of neoplasia. Chromoendoscopy was proven to be the most sensitive modality for dysplasia detection in several clinical trials, but a new study has now shown it to be an effective screening strategy in a routine clinical setting, further warranting its implementation into real-world practice.

Raja Atreya
Markus F. Neurath
News & Views16 Nov 2016
Nature Reviews Gastroenterology & Hepatology

Volume: 13, P: 688-690
Hobit- and Blimp-1-driven CD4⁺ tissue-resident memory T cells control chronic intestinal inflammation

Tissue-resident memory T cells (T_RM cells) have well-described functions in the protective response to infectious agents. Neurath and colleagues demonstrate that intestinal T_RM cells can also have key pathogenic roles in inflammatory bowel disease.

Sebastian Zundler
Emily Becker
Markus F. Neurath
Research28 Jan 2019
Nature Immunology

Volume: 20, P: 288-300
The IL-22–oncostatin M axis promotes intestinal inflammation and tumorigenesis

Hegazy and colleagues demonstrate that epithelial oncostatin M receptor expression drives gut inflammation and tumor formation.

Roodline Cineus
Yanjiang Luo
Ahmed N. Hegazy
ResearchOpen Access30 May 2025
Nature Immunology

Volume: 26, P: 837-853
Rapid single-cell physical phenotyping of mechanically dissociated tissue biopsies

A method for the sequential assessment of the physical phenotypes of suspended cells singularized from tissue biopsies by mechanical dissociation allows for rapid diagnoses.

Despina Soteriou
Markéta Kubánková
Jochen Guck
ResearchOpen Access06 Apr 2023
Nature Biomedical Engineering

Volume: 7, P: 1392-1403
Molecular pathways controlling barrier function in IBD

Several key studies published in 2014 have shed light on the pathogenesis of IBD by investigating the molecular mechanisms controlling mucosal homeostasis and intestinal barrier function. These studies revealed that alterations of intestinal homeostasis drive chronic intestinal inflammation. Here, we describe these findings and discuss future directions for translational research in IBD.

Raja Atreya
Markus F. Neurath
News & Views02 Dec 2014
Nature Reviews Gastroenterology & Hepatology

Volume: 12, P: 67-68
Development of therapy for and prediction of IBD — getting personal

The central studies published in 2017 address novel IBD therapeutic strategies and prediction of the future disease course or response to a distinct therapy. Together, these studies contribute to the understanding of the regulation of mucosal homeostasis and at the same time serve to develop novel personalized treatment algorithms in patients in whom a severe disease course can be predicted.

Raja Atreya
Britta Siegmund
News & Views06 Dec 2017
Nature Reviews Gastroenterology & Hepatology

Volume: 15, P: 72-74
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19.

David Simon
Koray Tascilar
Georg Schett
ResearchOpen Access24 Jul 2020
Nature Communications

Volume: 11, P: 1-7
Molecular imaging in gastroenterology

This Review summarizes advances in molecular imaging approaches and provides an overview of molecular beacons and targets, as well as endoscopic devices for imaging. Studies on detection and characterization of lesions are put in perspective along with current challenges for this innovative approach.

Raja Atreya
Martin Goetz
Reviews16 Jul 2013
Nature Reviews Gastroenterology & Hepatology

Volume: 10, P: 704-712
E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis

Patankar et al. identify E-type prostanoid receptor 4 as a negative regulator of tumour necrosis factor signalling and mixed-lineage kinase domain-like pseudokinase activation, thereby suppressing necroptosis of intestinal epithelial cells and promoting resolution of intestinal inflammation.

Jay V. Patankar
Tanja M. Müller
Christoph Becker
Research08 Jul 2021
Nature Cell Biology

Volume: 23, P: 796-807
T_H9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells

The T_H9 subset of helper T cells has specialized roles in parasite immunity. Neurath and colleagues show that T_H9 cells are also important for the pathogenesis of mouse and human colitis by disrupting gut barrier function.

Katharina Gerlach
YouYi Hwang
Markus F Neurath
Research08 Jun 2014
Nature Immunology

Volume: 15, P: 676-686
Interrogating host immunity to predict treatment response in inflammatory bowel disease

IBD treatment has an expanding repertoire of drugs targeting different aspects of the immune response. This Review focuses on unravelling the complexity of mucosal immune responses in IBD pathogenesis and how analytical assays might be harnessed to effectively stratify and individualise IBD therapy.

Jonathan L. Digby-Bell
Raja Atreya
Nick Powell
Reviews25 Nov 2019
Nature Reviews Gastroenterology & Hepatology

Volume: 17, P: 9-20
Location is important: differentiation between ileal and colonic Crohn’s disease

Evidence suggests that ileal Crohn’s disease is distinct from colonic Crohn’s disease on a multitude of layers. This Review provides a structured overview of this evidence and its implications for clinical decision-making.

Raja Atreya
Britta Siegmund
Reviews12 Mar 2021
Nature Reviews Gastroenterology & Hepatology

Volume: 18, P: 544-558
LPA receptor 1 (LPAR1) is a novel interaction partner of Filamin A that promotes Filamin A phosphorylation, MRTF-A transcriptional activity and oncogene-induced senescence

Andreas Konopa
Melanie A. Meier
Susanne Muehlich
ResearchOpen Access28 Dec 2022
Oncogenesis

Volume: 11, P: 1-12
Beyond endoscopic assessment in inflammatory bowel disease: real-time histology of disease activity by non-linear multimodal imaging

Olga Chernavskaia
Sandro Heuke
Jürgen Popp
ResearchOpen Access13 Jul 2016
Scientific Reports

Volume: 6, P: 1-11

Search

Author Correction: E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis

In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease

Author Correction: Hobit- and Blimp-1-driven CD4⁺ tissue-resident memory T cells control chronic intestinal inflammation

Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cells

Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019

Correction: Corrigendum: T_H9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells

Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study

Chromoendoscopy in IBD: indispensable in real-life screening

Hobit- and Blimp-1-driven CD4⁺ tissue-resident memory T cells control chronic intestinal inflammation

The IL-22–oncostatin M axis promotes intestinal inflammation and tumorigenesis

Rapid single-cell physical phenotyping of mechanically dissociated tissue biopsies

Molecular pathways controlling barrier function in IBD

Development of therapy for and prediction of IBD — getting personal

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Molecular imaging in gastroenterology

E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis

T_H9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells

Interrogating host immunity to predict treatment response in inflammatory bowel disease

Location is important: differentiation between ileal and colonic Crohn’s disease

LPA receptor 1 (LPAR1) is a novel interaction partner of Filamin A that promotes Filamin A phosphorylation, MRTF-A transcriptional activity and oncogene-induced senescence

Beyond endoscopic assessment in inflammatory bowel disease: real-time histology of disease activity by non-linear multimodal imaging

Search

Quick links

Search

Filter By:

Search

Quick links